Researchers from University of Washington presented the discovery of novel bumped kinase inhibitor (BKI) derived compound (BKIDC), BKIDC-1553, being developed for the treatment of prostate cancer.
Montara Therapeutics Inc. has received $8 million seed financing from several investors to further its development of its ’binary pharmacology’ for diseases of the brain.
Researchers from the Second Affiliated Hospital of Fujian Medical University and Shaoxing People's Hospital presented preclinical data for the signal transducer and activator of transcription 3 (STAT3) inhibitor STX-0119, which has been previously validated in models of cancer.
Scientists at Boehringer Ingelheim GmbH have made the ketohexokinase (KHK) inhibitor BI-9787 freely available as a tool compound via the company’s Opnme program.
DeepSA, an edit-based generative framework that utilizes deep simulated annealing (SA), was used to develop novel local anesthetics with multiple activities. Researchers from Sichuan University applied DeepSA to generate over 400 analogs of the local anesthetic articaine.
Researchers from Northeast Normal University in Changchun demonstrated that compound AW-01178 reversed the abnormal regulation of E-cadherin by inhibiting the class I HDAC enzyme.
Beijing DP Technology Co. Ltd. has nominated DPT-0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a preclinical candidate for the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME).
Even though the treatment options that exist for acute myeloid leukemia (AML) are growing, the clinical outcome of patients is still unfavorable. In AML dysregulation of the tyrosine kinase receptors, including RAS, RAF, MEK and ERK, and of the Aurora kinase family (AURK) exists, are both tied to AML development and progression.
Molecure SA has confirmed the in vitro activity of a molecule binding to a new mRNA target within its mRNA discovery platform. This represents the discovery of another class of molecules binding to a second mRNA biological target, which has been confirmed in in vitro assays.
Interstitial lung fibrotic disease (ILD) is characterized by inflammation and fibrosis of lung tissue and is associated with poor prognosis. Gat Therapeutics SL has developed GTX-011, an orally available small molecule for treating fibrotic diseases.